Astellas PharmaALPMF 72 Receivables Turnover is 0.70 as of Mar. 2026. GuruFocus rates ALPMF with a GF Score™ of 72/100 and a GF Value™ of $14.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 946 Drug Manufacturers companies, Astellas Pharma ranks worse than 81.5% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Astellas Pharma's Revenue for the
three
months ended in Mar. 2026 was $3,390 Mil. Astellas Pharma's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4,847 Mil.
Hence, Astellas Pharma's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.70.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Astellas Pharma Receivables Turnover Related Terms
Astellas Pharma Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: Receivables Turnover Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Receivables Turnover of 0.70 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Astellas Pharma and its competitors. According to the industry distribution chart, Astellas Pharma ranks #771 out of 946 companies in the Drug Manufacturers industry, placing it in the top 81.5%.
Is Astellas Pharma's Receivables Turnover too high?
Astellas Pharma's current Receivables Turnover is 0.70. The Drug Manufacturers industry median Receivables Turnover is 5.07. Astellas Pharma's value of 0.70 is 86.2% below this industry median. Based on the distribution chart, Astellas Pharma ranks #771 out of 946 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Astellas Pharma has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Receivables Turnover compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #771 out of 946 companies for Receivables Turnover. This places Astellas Pharma in the lower half of its industry. The industry median Receivables Turnover is 5.07. Astellas Pharma's value of 0.70 is 86.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Receivables Turnover of 0.70 is 86.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Receivables Turnover is 0.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.18, compared to a current price of $14.60 — trading 3% above its estimated fair value. The current Receivables Turnover is 0.70 and 86.2% below the Drug Manufacturers industry median of 5.07. Astellas Pharma's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Receivables Turnover is 0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued.
The current stock price of $14.60 is trading 3% above its estimated GF Value™ of $14.18.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Receivables Turnover: 0.70
GF Value™: $14.18 vs. price of $14.60 (3% above fair value)
Industry Position: 86.2% below the Drug Manufacturers median (#771 of 946)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
72GF Score
Get the complete analysis for ALPMF
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
